| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 544405000 | Additional hetero ring which is unsaturated | 18 |
| 20090143583 | TRANSFECTION REAGENTS - Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: | 06-04-2009 |
| 20090221824 | ENANTIOSELECTIVE PROCESS - A process for the production of compounds comprising the enantioselective hydrogenation of 2-substituted acrylic acid derivatives. | 09-03-2009 |
| 20100041886 | ISOXAZOLO-PYRAZINE DERIVATIVES - The invention relates to isoxazolo-pyrazine derivatives and their pharmaceutically acceptable salts having affinity and selectivity for the GABA A α5 receptor binding site, their manufacture, and pharmaceutical compositions containing them. The compounds of present invention are inverse agonists of GABA A α5. The invention also relates to methods for enhancing cognition and for treating cognitive disorders like Alzheimer's disease. | 02-18-2010 |
| 20100094009 | NOVEL CRYSTALLINE COMPOUND USEFUL AS GLK ACTIVATOR - A novel crystalline form of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1-methylethyl)oxy]-N-1H-pyrazol-3-ylbenzamide is described in the specification. This compound is a glucokinase (GLK or GK) activator and useful as a pharmaceutical agent in the treatment or prevention of a disease or medical condition mediated through GLK, leading to a decreased glucose threshold for insulin secretion. Processes for the manufacture of the crystalline form, pharmaceutical compositions comprising the crystalline form and the use of the crystalline form in medical treatment are also described. | 04-15-2010 |
| 20100094010 | CHEMICAL PROCESS - Processes for preparing compounds of Formula I and IV | 04-15-2010 |
| 20100249413 | STABILIZED PHARMACEUTICAL COMPOSITION - [Problem] A stable liquid-form pharmaceutical composition wherein the decomposition with time is prevented and a stabilization method thereof is provided, for providing a liquid-form pharmaceutical composition of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium or a pharmaceutically acceptable salt thereof to a clinical field. | 09-30-2010 |
| 20110105753 | PROCESS FOR THE PREPARATION OF PYRAZINONE THROMBIN INHIBITOR AND ITS INTERMEDIATES - Improved process for the preparation of 3-fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide of formula (I) and its intermediates is provided. | 05-05-2011 |
| 20110152524 | PHARMACEUTICAL COMPOSITION CONTAINING 1,2-DITHIOLTHIONE DERIVATIVE FOR PREVENTING OR TREATING DISEASE CAUSED BY OVEREXPRESSION OF LXR-ALPHA - Provided is a pharmaceutical composition that contains a 1,2-dithiolthionederivative, and is effective to prevent and treat a disease caused by overactivity of a liver X receptorα (LXRα) or a sterol response element binding protein (SREBP-1). Specifically, the pharmaceutical composition includes 1,2-dithiolthione derivatives such as 4-methyl-5-(2-pyrazinyl)-1,2-dithiol-3-thione, 3-methyl-1,2-dithiol-3-thione, or 5-(6-methoxypyrazinyl)-4-methyl-1,2-dithiol-3-thione. The pharmaceutical composition is effective for preventing and treating hypertension caused by renin, aldosteronism, adrenoleukodystrophy, glomerulosclerosis, proteinuria, nephropathy, liver steatosis, hypertriglyceridemia or hyperreninemia. | 06-23-2011 |
| 20120108817 | ACETYL PYRROLIDINYL INDOLE DERIVATIVE - The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R | 05-03-2012 |
| 20120190853 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of structural formula (I) or (III): | 07-26-2012 |
| 20120245353 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND - A nitrogen-containing heterocyclic compound is represented by Formula (I): wherein R | 09-27-2012 |
| 20130225819 | USE OF AZIDES IN SYNTHESIS - Described herein are inventive methods for synthesis of tetrazoles. In some embodiments, the method involves the use of a flow reactor. The methods provided herein are capable at being carried out in short reaction times, with high yields, with minimal side reactions, and/or with minimal chance of explosions caused by the presence of azides. | 08-29-2013 |
| 20140213788 | PROCESS FOR THE PREPARATION OF ALPHA-ACYLOXY BETA-FORMAMIDO AMIDES - The present invention relates to a process for the preparation of a compound of the general Formula (I), comprising: a) reacting a compound of the general Formula (II) with a compound of the Formula III R | 07-31-2014 |
| 20140316137 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES - Coelenterazine analogs with different luminescence properties from conventional ones and coelenteramide analogs with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogs modified at the 8-position of coelenterazine and coelenteramide analogs modified at the 2- or 3-position of coelenteramide. | 10-23-2014 |
| 20150322052 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS - The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blocker such as Na | 11-12-2015 |
| 20160376259 | Methods for Preparing Oltipraz - The invention provides improved methods of synthesizing oltipraz, which result in higher overall yield and better purity of the desired product. | 12-29-2016 |
| 20160376260 | Slow Release of Organoboronic Acids in Cross-Coupling Reactions - A method of performing a chemical reaction includes reacting a compound selected from the group consisting of an organohalide and an organo-pseudohalide, and a protected organoboronic acid represented by formula (I) in a reaction mixture: | 12-29-2016 |
| 20220135571 | THERAPEUTIC EGFR INHIBITORS - The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds. | 05-05-2022 |
